Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on June 11, 2015, 11:40:35 am
-
The National AIDS Treatment Advocacy Project now reports that Gilead’s Harvoni and the combination of Gilead’s Sovaldi with Bristol-Myers Squibb’s as-yet-unapproved daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of HIV/hepatitis C virus coinfected adults.
Not as good: Olysio + Sovaldi, Viekira Pak
For more information: http://www.hepmag.com/articles/DDIs_HCV_HIV_2501_27364.shtml